Compare Levi Strauss & Co. (LEVI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Levi Strauss & Co. trades at $19.56 (market cap $7.47B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Levi Strauss & Co. and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Levi Strauss & Co. pays a 3.29% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 71 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LEVI | SYRE | |
|---|---|---|
Market Cap | $7.47B | $7.52B |
Volume | 6,427,839 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $108.92 |
52-Week Low | $17.92 | $22.18 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $9.02B | $6.52B |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.57, up 1.72% with strong fundamentals including a 12.82 P/E ratio and 25.76% ROE. The stock shows bearish technical signals but has consistently beaten earnings expectations for four consecutive quarters. Recent news highlights the company's successful '90s fashion revival and appointment of a new CFO, while analyst consensus remains strongly bullish with a $29 price target representing 48% upside potential.
The investment case balances attractive valuation against technical weakness. Strong profitability metrics and consistent earnings beats support upside, but bearish technical indicators and execution risks in the competitive apparel sector warrant caution. The 78.95% buy rating from analysts suggests significant institutional confidence in Levi's growth trajectory despite near-term market sentiment concerns.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
